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ProteinkinaseCs(PKCs)constituteafamilyofserine/threoninekinases,whichhasdistinguishedandspeciﬁcrolesinregulating
cardiac responses, including those associated with heart failure. We found that the PKCh isoform is expressed at considerable
levels in the cardiac muscle in mouse, and that it is rapidly activated after pressure overload. To investigate the role of PKCh in
cardiac remodeling, we used PKCh
 /  mice. In vivo analyses of PKCh
 /  hearts showed that the lack of PKCh expression leads
to left ventricular dilation and reduced function. Histological analyses showed a reduction in the number of cardiomyocytes,
combined with hypertrophy of the remaining cardiomyocytes, cardiac ﬁbrosis, myoﬁbroblast hyper-proliferation and matrix
deposition. We also observed p38 and JunK activation, known to promote cell death in response to stress, combined with
upregulationofthefetalpatternofgeneexpression,consideredtobeafeatureofthehemodynamicallyormetabolicallystressed
heart. In keeping with these observations, cultured PKCh
 /  cardiomyocytes were less viable than wild-type cardiomyocytes,
and, unlike wild-type cardiomyocytes, underwent programmed cell death upon stimulation with a1-adrenergic agonists and
hypoxia. Taken together, these results show that PKCh maintains the correct structure and function of the heart by preventing
cardiomyocyte cell death in response to work demand and to neuro-hormonal signals, to which heart cells are continuously
exposed.
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The heart responds to different pathological stimuli, which
make it function harder under conditions of hemodynamic
overload, by inducing an increase in muscle mass, triggering
left ventricular (LV) hypertrophy.
1 This remodeling is con-
sidered a compensatory response to the altered workload,
allowing the heart to function harder under conditions of
sustained stress. However, LV hypertrophy is clinically
associated with a signiﬁcant increase in the risk of heart
failure, dilated cardiomyopathy, ischemic heart disease and
sudden death, leading to increased cardiovascular mortality.
Actually, LV hypertrophy is often followed by LV dilation,
which is a reduction in muscle mass, an increase in ﬁbrotic
tissue and an enlargement in cavity diameter. This further
remodeling results in functional alterations and eventually
in the development of heart failure.
1 Many studies have
suggested that members of the protein kinase C (PKC) family
have a role in cardiac structure. Early studies have shown that
TPA,a knownPKC activator,activatesthe fetalgene program
and increases cardiomyocyte size.
2,3 However, as the family
of serine/threonine protein kinases C comprises at least 12
isoforms, those early studies were somewhat unspeciﬁc.
Later studies, in fact, showed that many of the PKC isoforms
are expressed at appreciable levels in the myocardium and
selectively regulate a number of cardiac responses, including
those associated with heart failure.
4 PKCs can be subdivided
in threesubgroups, accordingtotheir structure andenzymatic
activity: ‘conventional’ PKCs (PKC a, b1, b2 and g), the
enzymatic activity of which is calcium and phospholipid
dependent; ‘novel’ PKCs (d, e, Z, y and m/PKD), the activity
of which is calcium independent but phospholipid dependent;
and ‘atypical’ PKCs (z, i/l and t), the activity of which is
calcium and phospholipid independent. PKCa activation was
found to precede the hypertrophy induced by the over-
expression of the L-type voltage-dependent calcium channel
in an animal model,
5 and its overexpression in cultured
cardiomyocytes induces hypertrophy.
6 By contrast, the
absence of PKCa prevents the transition from cardiac
hypertrophy to failure.
7 PKCa is not the only PKC isoform
involved in the maintenance of cardiac structure. Over-
expression of PKCb1 also induces cardiac hypertrophy and
sudden death in animal models, although its ablation does not
abolish the hypertrophy induced by either pressure overload
or infusion with hypertrophic agonists.
8,9 PKCe is considered
the most important isozyme protecting the heart from
ischemia and reperfusion injury. Indeed, PKCe overexpres-
sion induces cardiac hypertrophy, but with preserved systolic
function, suggesting an important role of PKCe for the
development of ‘compensatory’ hypertrophy.
10 PKCy is
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www.nature.com/cddisknown to have a crucial role in T-lymphocyte activation
and to mediate various cellular responses in the skeletal
muscle.
11–17 However, little is known about PKCy activity in
cardiac function and remodeling. Calcineurin-induced hyper-
trophic signaling is associated with PKCa and PKCy activa-
tion, both in vivo and in vitro.
18 In addition, PKCy has been
shown, along with the other members of the ‘novel’ PKCs
subclass, to regulate localization of class II histone deacety-
lases (HDACs) in different cell systems.
15,19 In the heart,
HDACs act as inhibitors of cardiac hypertrophy, and PKC-
dependent nuclear export of HDAC5 is a critical event in
the signaling cascade in cardiac hypertrophy.
19
WeobservedthatPKCyisexpressedatconsiderablelevels
in the cardiac muscle in mouse, and that it is rapidly activated
after pressure overload, suggesting that it may have a role in
cardiac response to environmental stimuli. We thus aimed to
deﬁne the possible role of PKCy in cardiac structure and
function.
Results
PKCh is expressed in cardiomyocytes, and it is rapidly
activated after pressure overload. First, the expression
of PKCy in cardiac muscle was analyzed by double
immunoﬂuorescence analysis: as shown in Figure 1A,
PKCy expression is restricted to myosin heavy-chain
(MyHC)
þ cardiomyocytes. As expected, no PKCy immuno-
reactivity was detectable in the PKCy
 /  hearts (Figure 1A).
Moreover, western blot analysis showed that the lack of PKCy
expression did not alter the expression levels of other PKC
isoforms, such as PKCa or members of the novel class of
PKCs, such as PKCd,P K C e and PKCZ (Figure 1B). To verify
whether PKCy activity may be involved in cardiac remodeling,
10- to 16-week-old WT male mice were subjected to cardiac
pressure overload through transverse aortic constriction
(TAC). As control, a parallel group of mice was sham
operated. After 15min, the hearts were removed and total,
Figure 1 PKCyisexpressedincardiomyocytesanditisrapidlyactivatedafterpressureoverload.(A)ImmunolocalizationofPKCyincryosectionsofLVfrom2-month-old
WT mice (a). Lack of PKCy expression in PKCy
 /  LV is shown in b. The a-MyHC MF20 antibody (green) was used to identify cardiomyocytes (c, WT; d, PKCy
 / ).
(Bar¼50mm). (B) Western blot analysis of PKC isoforms expression in LV from 2-month-old WT and PKCy
 /  mice. Representative experiment is shown (n¼9 per
genotype).Thea-tubulinlevelofexpressionwasusedfornormalization.(C)Leftpanel:representativewesternblotoftheindicatedPKCisoformscontentinbothcytosolic(Cy)
and particulate (P) subcellular protein fractions, after 15min transverse aortic constriction (TAC). Sham-operated mice (Sham) were used as controls. Right panel:
densitometric analysis of the results obtained from western blots of the indicated PKC isoforms content in subcellular protein fractions (empty portion of each
column¼particulate fraction, P; gray portion¼cytosolic fraction, Cy) expressed as relative percentage, with 1.0 given as the total level of expression of each isoform. The
resultswereobtainedas the meanvalue (±S.D.)of western blotspreparedfrom proteinsubcellular fractionsof singleanimals (n¼8 per genotype:4 sham operated,S, and
4 subjected to TAC, T). (D) Western blot analysis of the phosphorylated (active) form of PKCy (
Thr538p-PKCy) in total protein fractions, after 15min TAC. The phospho/total
PKCy ratio was evaluated by densitometric analysis and shown in the right. S¼sham; T¼TAC. *Po0.01
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prepared for western blot analysis. As shown in Figure 1C,
PKCy rapidly translocated to the membrane fraction after
TAC. Among the other isoforms analyzed, both PKCa and
PKCe, the activation of which is known to be linked to cardiac
hypertrophic response, also translocated to the membrane
fraction, whereas no PKCd membrane translocation was
observed, after 15min of TAC. PKCy activation was also con-
ﬁrmed by western blot analysis using an anti-
Thr538p-PKCy-
speciﬁc antibody: after TAC, a higher fraction of the total
PKCy is phosphorylated (activated) as compared with
sham-operated hearts (Figure 1D).
The lack of PKCh expression results in LV dysfunction.
To assess the effect of the lack of PKCy expression on
cardiac structure and function, echocardiographic analyses
were performed in 10- to 16-week-old male mice compared
with age- and sex-matched WT mice (10 mice per genotype).
LV diameters, wall thickness and contractile function
were evaluated at basal conditions. LV from PKCy
 /  mice
displayed reduced wall thickness and enlarged diameter,
when compared with WT mice (Table 1). These ﬁndings
are consistent with a pathological phenotype of dilated
cardiomyopathy. As expected, a signiﬁcant reduction in
contractile performance was observed. Indeed, ablation of
PKCy induced a 25–29% reduction in fractional shortening,
associated with a parallel reduction in ejection fraction
(Table 1). This defect in contractility was conﬁrmed by the
more accurate hemodynamic analysis of the pressure–
volume curves (Table 2), which showed that end-systolic
volume was increased, whereas stroke volume and end-
systolic elastance were decreased in PKCy
 /  mice, when
compared with WT mice.
The lack of PKCh expression induces cardiac
ﬁbrosis. To identify the LV characteristics that led to
the observed cardiomyopathic phenotype, we performed
histological analyses on the hearts of PKCy
 /  and WT mice.
Gomori’s trichrome staining of 2-month-old PKCy
 /  LV
cryosections revealed a signiﬁcant increase in interstitial
ﬁbrosis when compared with age-matched WT LVs
(Figure 2A). RT-PCR showed that the observed ﬁbrosis
was associated with an increase in the expression of
collagens 1a1 and 3a1 (the main constituents of the cardiac
extracellular matrix), as well as of a-SMA, a primary marker
of ﬁbroblast-to-myoﬁbroblast conversion and TGFb,a
ﬁbrogenic growth factor (Figure 2B). Quantiﬁcation of the
ﬁbrosis areas at different time points during postnatal life
showed that in newborn mice, there was no signiﬁcant
increase in ﬁbrosis in the LVs of either genotype; by contrast,
a highly signiﬁcant increase in the accumulation of interstitial
ﬁbrosis in PKCy
 /  mice was observed with age, when
compared with age-matched WT mice (Figure 2C).
To determine whether this increased ﬁbrosis was due to the
altered proliferation/activity of cardiac ﬁbroblasts (CFs), cell
proliferation was evaluated in vivo by 5-bromo-20-deoxy-
uridine (BrdU) incorporation. Figure 3A shows that a
signiﬁcant increase in the percentage of BrdU
þve cells was
evident in 2-month-old PKCy
 /  hearts, compared with WT
hearts, and that BrdU
þve cells were localized in interstitial,
myosin
 ve areas, and can thus be regarded as CFs. The
increased cell proliferation in PKCy
 /  hearts was also
conﬁrmed by the increase in PCNA (a marker of the S phase)
and Cyclin D1 (a marker of the G1/S phase transition)
expression, as revealed by RT-PCR analysis (Figure 3A). To
conﬁrm that PKCy ablation leads to proliferation of CFs, these
cells were also isolated from LVs of 1- to 3-day-old mice and
their proliferation capability was analyzed in vitro. As shown in
Figure 3B, a 60% increase in BrdU
þve cells was observed
in cultured PKCy
 /  CFs, when compared with WT CFs. This
increase was associated with a signiﬁcant upregulation of
Coll 1a1 expression.
The lack of PKCh expression induces hypertrophy of
cardiomyocytes but reduces their number. Hematoxylin/
eosin staining of LV from 2-month-old mice also showed that
the cardiac ﬁbrosis we observed was associated with an
increase in cardiomyocyte size (Figure 4A). The cross-
sectional area (CSA) of LV cardiomyocytes was evaluated by
a-caveolin-3 (cardiomyocyte-speciﬁc) immunoﬂuorescence,
at different time points during postnatal life. As shown in
Figure 4B, cardiomyocyte CSA was increased in PKCy
 / 
Table 1 Echocardiographic characterization of WT and PKCy
 / mice
Parameter WT PKCh
 / 
RRs (mmHg) 107±4 117±3
LVID (mm) 3.185±0.16 3.74±0.40
LVPW (mm) 0.72±0.02 0.60±0.08
IVS (mm) 0.74±0.02 0.61±0.07
FS (%) 53.9±3.8 38.07±7.8*
LV%EF 82.5±26 8 ±2.2*
RRs, systolic blood pressure; LVID, left ventricular end-diastolic diameter;
LVPW, left ventricular posterior wall thickness in end diastole; IVS, inter-
ventricular septum thickness in end diastole; %FS, percentage fractional
shortening; LV%EF, left ventricular percentage ejection fraction. *Po 0.01
versus WT.
Table 2 Hemodynamic parameters in WT and PKCy
 /  mice
Parameter WT PKCh
 / 
HR, b.p.m. 269.5±22.0 291.8±18.1
ESV, ml 24.2±2.6 44.1±5.9*
EDV, ml 64.6.±3.9 75.8±8.2
Systolic function
Max pressure, mmHg 88.8±4.4 89.9±5.5
ESP, mmHg 82.6±4.7 82.1±5.5
dP/dtmax, mmHg per s 5249±380 5238±526
EF, % 67.5±1.9 49.2±1.7*
SV, ml 46.4±2.0 37.8±2.8*
Ees, mmHg/ml 1.7±0.3 0.9±0.2*
Diastolic function
EDP, mmHg 4.6±0.8 6.0±1.5
dP/dtmin, mmHg per s  3994±477  4851±591
t (Glantz), msec 21.0±2.1 16.0±1.1
EDPVR, mmHg/ml 0.2±0.1 0.3±0.1
HR, heart rate; ESV, end-systolic volume; EDV, end-diastolic volume; ESP,
end-systolic pressure; EF, ejection fraction; SV, stroke volume; Ees, elastance,
end-systolic; EDP, end-diastolic pressure; EDPVR, end-diastolic pressure–
volume relationship. *Po0.05 versus WT.
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Cell Death and Diseasemice at all ages examined. Moreover, this increase in
cardiomyocyte size was associated with a signiﬁcant
reduction in the number of cells at all ages examined. In
fact, as shown in Figure 4B, y-ablation resulted in a reduction
in the number of cardiomyocytes, ranging from 10%, at
1 month of age, up to 25% in subsequent growth phases,
when compared with age- and sex-matched WT mice.
Thus, we analyzed signaling proteins involved in cardio-
myocyte death in response to hypertrophic and stress stimuli,
namely p38 and JNK mitogen-activated protein (MAP)
kinases.
20 We observed that p38 and JNK phosphorylations
were both markedly higher in 2-month-old PKCy
 /  LVs than
in WT LVs. By contrast, phosphorylation levels of ERK1/2,
which is implicated in cell proliferation/survival, were not
altered (Figure 4C). Moreover, we analyzed the activation of a
fetal gene expression program, which is usually associated
with pathological LV remodeling. RT-PCR analysis showed
that the expression of genes encoding atrial natriuretic factor
(ANF), a-skeletal actin (a-SKA) and the fetal b-myosin heavy
chain (b-MyHC), although barely detectable in LVs from
2-month-old WT mice, was high in LVs from age- and sex-
matched PKCy
 /  mice (Figure 4D). Moreover, in PKCy
 / 
LVs, the increased a-SKA mRNA level was associated with
decreased a-cardiac actin (a-CAA) expression, when com-
pared with WT LVs, where a-CAA isoform expression
accounts for most of the actin expressed (Figure 4D).
Interestingly, although the low level of a-SKA expression
remained constant in LVs from WT mice, a progressive age-
related increase was observed in the a-SKA transcript level
in PKCy
 /  hearts (data not shown).
PKCh is required for cardiomyocyte survival. Next,
we investigated whether the phenotype we observed was
due to an impaired sensitivity to extracellular signals, to
which heart cells are continuously exposed and which leads
to cardiomyocyte death. Thus, we analyzed the adaptive
response of cultured cardiomyocytes to such signals.
Neonatal CMCs were isolated from 1- to 3-day-old
PKCy
 /  and WT mice. Morphological analysis showed
that PKCy
 /  CMCs were signiﬁcantly larger (by B50%)
than WT CMCs (Figure 5A and B), reﬂecting the size
increase observed in vivo. Moreover, actin ﬁlament
organization resembled a hypertrophic phenotype, forming
‘stress ﬁber-like structures’, as shown by F-actin staining with
phalloidin (data not shown). To examine the role of PKCy in
the adaptive response of CMCs to work demand, CMCs were
stimulated with phenylephrine (PE), the a1-adrenergic
agonist. As expected, after 48h of treatment, WT CMCs
increased in size, reaching a size similar to that observed in
untreated PKCy
 /  CMCs. Accordingly, ANF expression was
not detectable in untreated WT CMCs, whereas PE treat-
ment induced evident perinuclear ANF protein accumulation.
By contrast, upon agonist exposure, size was signiﬁcantly
reduced in PKCy
 /  CMCs (Figure 5A and B). Moreover, the
perinuclear ANF protein accumulation, already evident in
untreated PKCy
 /  CMCs, was signiﬁcantly reduced upon
exposure to the agonist (Figure 5A). Similar results were
obtained when CMCs were exposed to endothelin-1 or
angiotensin II (data not shown).
To investigate the ‘pathological’ response to hypertrophic
stimuli, the expression and activation of factors involved in the
hypertrophic transduction pathways were analyzed in both
WT and PKCy
 /  CMCs, either treated with or without PE. As
expected, when WT CMCs were treated with PE for 30min, a
signiﬁcant30%increaseinAkt phosphorylationwas observed
by western blot analysis as a result of the hypertrophic
response. By contrast, no increase in Akt phosphorylation
was observed in PKCy
 /  CMCs upon PE treatment.
(Figure 5B).
When WT CMCs were treated with PE for longer periods of
time(48h),anincreaseinboththeANFandMyHCexpression
levels was observed, as expected. By contrast, the higher
basal expression level of both ANF and MyHC in PKCy
 / 
CMCs,ifcomparedwiththatofWTCMCs,wasreducedbythe
treatment (Figure 5B). Moreover, western blot analysis
showed that cardiac troponin I (cd-TnI) intracellular content
was signiﬁcantly lower (B30%) in PKCy
 / CMCs than in
WT CMCs, and was further reduced upon PE treatment
(Figure 5B). No signiﬁcant differences in cd-TnI expression
Figure 2 PKCy ablation results in increased ﬁbrosis. (A) Gomori’s trichrome-
stained representative cryosections of LV from 2-month-old WT (a and c) and
PKCy
 /  mice (b and d); a–b: bar¼2mm; c–d: bar¼200mm. (B) RT-PCR
analysisof theindicatedﬁbroticmarkersin LVsfrom2-month-oldWTandPKCy
 / 
mice (3 mice per genotype). Col1a1: a1 collagen 1; Col3a1: a1 collagen 3; aSMA:
a-smooth muscle actin; TGFb1: transforming growth factor b1; GAPDH expression
was used to normalize the reaction. (C) Quantiﬁcation of interstitial ﬁbrosis was
examined at the indicated postnatal ages of WT (empty bars) and PKCy
 /  (ﬁlled
bars) LVs, expressedas a percentage of thetotal area of the entire section.At least
three sections per mouse were analyzed (n¼3 per genotype/age). *Po0.01;
**Po0.001; ***Po0.0001
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Cell Death and Diseasewere observed in WT CMCs, regardless of whether they were
exposed to PE. Degradation and/or release of regulatory
myoﬁbrillar proteins, such as cd-TnI or cd-TnT, are known to
occur upon cardiomyocyte damage.
21
Trypan blue and TUNEL analyses were then used to
investigate whether treatments induced cell death in PKCy
 / 
CMCs (Figure 5C). At basal conditions in serum-free medium,
the percentage of PKCy
 /  CMCs permeable to trypan blue
was already 2.5 times higher than in WT cells. PE exposure
(48h)resultedinafurtherincreaseinthepercentageoftrypan
blue-positive CMCs, when compared with untreated PKCy
 / 
CMCs. No differences were observed in WT cells upon
treatment. Similar results were obtained when CMCs were
exposed to endothelin-1 or angiotensin II, as well as to
environmentalstressstimuli,suchashypoxicconditions(data
notshown).Toverifywhethertheobservedcelldeathwasdue
toproteaseactivity,CMCsweretreatedwithleupeptin(Leu),a
protease inhibitor preferentially active on calpains, before
being exposed to PE. A 30-min Leu pretreatment, followed by
48h of exposure to PE, signiﬁcantly reduced trypan blue-
positive PKCy
 /  CMCs to a level comparable with WT CMCs
(Figure 5C).
TUNEL analysis was performed to assess whether the cell
death we observed was due to apoptosis. At basal conditions
in serum-free medium, the percentage of TUNEL-positive
nuclei was already higher in PKCy
 /  than in WT cells
(Figure 5D). PE exposure (48h) induced, in PKCy
 /  CMCs,
a further increase (about three times) in the percentage
of apoptotic nuclei, if compared with unstimulated cells.
By contrast, no increase was detectable in PE-treated WT
CMCs (Figure 5D). Similar results were obtained using
endothelin-1 and angiotensin II treatments (data not shown).
To characterize which apoptotic pathway is active in the
absence of PKCy, PKCy
 /  and WT CMCs were treated with
or without PE for 4h; cleavage of caspase-9 and caspase-8
was analyzed by western blot. As shown in Figure 5E, the
caspase-9 proteolitic fragment (p35/36, the active form)
was evident in untreated PKCy
 /  CMCs, and it was further
accumulated after 4h PE treatment. Very little, if no, caspase-
9 cleavage was observed in WT CMCs, and PE exposure
induced a slight increasein p35/36accumulation. Bycontrast,
no cleaved/active fragments of caspase-8 were detectable in
both WT and PKCy
 /  CMCs, although a slight increase in
full-length caspase-8 accumulation was evident after 4h PE,
in both WT and PKCy
 /  CMCs to a similar extent.
Discussion
In this paper, we show that the expression/activity of the
y-isoform of PKCs ensures the correct structure and function
of cardiac muscle, at least in part, by protecting cardiomyo-
cytes from cell death.
Asﬁrst,PKCyisexpressedataconsiderablelevelinmouse
cardiomyocytes; moreover, it is strongly activated, together
with PKCa and PKCe, within 15min of aortic banding,
suggesting that it may have a pivotal role in the cardiac
response to pressure overload. Both PKCa and PKCe have
been implicated in cardiac hypertrophy, based on in vivo and
invitrostudies,althoughtheyprobablyhavedifferentroles.
4In
particular, PKCa is supposed to be involved in the transition
from hypertrophy to heart failure, whereas PKCe is believed to
be involved in compensatory hypertrophy.
7,22 The fact that
both isoforms are rapidly (within 15min) activated upon
pressure overload, which has never been investigated before,
Figure 3 PKCy ablation results in increased ﬁbroblast proliferation. (A) BrdU incorporation (green) in 2-month-old WT (a–c) and PKCy
 /  (d–f) LVs. Sections were
counterstained with Hoechst and a-MyHC antibody (red) (b–c and e–f). Representative micrograph of transverse sections at higher magniﬁcation is shown in c and f
(bar¼50mm). The percentage of BrdU
þve nuclei per section over the total number of nuclei is also shown (Po0.01 versus WT; n¼3 per genotype). RT-PCR analysis of
PCNAandCyclinD1expressionin2-month-oldWTandPKCy
 / LVsisshownintheright.GAPDHexpressionwasusedtonormalizethereaction.(B)Immunoﬂuorescence
analysis of BrdU incorporation in cultured CFs isolated from LV of 1- to 3-day-old WT and PKCy
 /  mice (bar¼50mm). The percentage of BrdU
þve nuclei per microscopic
ﬁeld over the total number of nuclei is also shown (Po0.01 versus WT). RT-PCR analysis of Coll 1a1 expression in WT and PKCy
 /  cultured CFs is shown in the right.
GAPDH expression was used to normalize the reaction
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Cell Death and Diseaseindicates that the actual outcome of the stimulus (maladaptive
or compensatory hypertrophy) depends on a delicate balance
between the different pathways. Interestingly, PKCd, the
activity of which has been proposed to be somehow
redundant to PKCe activity with respect to cardiac hypertro-
phy,
22 does not change. This observation suggests that,
unlike PKCe, PKCd is not involved in the early response to
pressure overload and does not behave exactly as PKCe.
Moreover, PKCd is structurally related to PKCy, which
behaves similarly to PKCe to pressure overload, instead.
Whether PKCy and PKCe, which belong to the same PKC
subfamily as PKCd, may have similar or speciﬁc roles in the
response of heart to pressure overload will need further
investigation.
However, the data reported in this paper show that the lack
of PKCy expression in vivo results in basal cardiac dysfunc-
tion, differently from what occurs in the absence of PKCe,
23
highlighting a possible distinguished and speciﬁc role for
PKCy in cardiac structure and function under physiological
conditions. Indeed, PKCy
 /  mice exhibit abnormalities in
several contractility indexes. In particular, the lack of PKCy
expression affects the ejection phase of the LV systole,
although it does not have any effect on the diastole or on the
isovolumic phase of systole. On this issue, indexes of the
ejection phase have been identiﬁed as the most reliable
parameter for detecting depressed myocardial function.
24
This loss of cardiac function is associated with a structural
defect, consisting of reduced wall thickness and greater LV
diameter. The combination of dilation and thinner muscle wall
reduces the efﬁciency of heart performance, which results in
lower contractile power per cardiac area. It is noteworthy that
in most of the animal models, lacking or overexpressing
speciﬁc PKC isoforms, altered cardiac function is only evident
in response to pathological stimuli.
4,23,25 Even ablation of
PKCe, which is considered the most important isozyme
protecting the heart from ischemia and reperfusion injury,
did not exert any basal cardiac phenotype, although the
combination of loss- and gain-of-function approaches, aimed
to modulate its translocation, suggested a role for PKCe
signaling in normal postnatal maturational myocardial devel-
opment, probably regulating cardiomyocytes prolifera-
tion.
22,23 This fact suggests that most PKC isoforms are
modiﬁers of heart response to speciﬁc stimuli, or that the
eventual redundancy between them can preserve basal
physiology in mutant models. By contrast, the absence of
PKCy affects the normal physiology of the heart. Thus, PKCy,
differently from any other isoform, may be considered a key
protein for cardiac structure and function under physiological
conditions. Moreover, the cardiomyopathy observed in
PKCy
 /  mice is associated with a profound alteration in the
cellular and extracellular structure of the heart. Indeed,
increased interstitial ﬁbrosis was observed in the absence of
PKCy. This increase occurs during postnatal heart growth, as
demonstrated by the fact that no differences were observed in
the hearts of newborn mice and that ﬁbrotic areas increased
with age. This is the result of increased myoﬁbroblast
proliferation and matrix deposition, as shown by both in vivo
and in vitro analyses, possibly as a consequence of the
progressive loss of cardiomyocytes observed in the hearts
lacking PKCy. As a result, the surviving cardiomyocytes
Figure 4 PKCy ablation induces CMC hypertrophy and loss, MAPK activation
andreexpressionofcardiacfetalgenes.(A)RepresentativeimagesofH&Estaining
of cryosections obtained from 2-month-old WT (a) and PKCy
 /  (b) mice LVs
(bar¼50mm).(B)Toppanel:meanCMCCSAinWTandPKCy
 / LVsatdifferent
time points during postnatal growth (d¼days, mo¼months); 40 microﬁelds per
mouse (B2000 myocytes each group) were analyzed, n¼3 each group. Bottom
panel:thenumberofCMCsinPKCy
 / LVsatdifferenttimepointsduringpostnatal
growth, expressed as the percentage of the number of CMCs in age-matched WT
LVs, with the number of WT CMCs considered as 100 (*Po0.01, **Po0.001,
***Po0.0001 versus WT). The number of CMCs in the heart was determined by
counting caveolin-3 and myosin
þve cells in 50 microscopic ﬁelds per cryosection
(n¼3 each group). (C) Western blot analysis of the indicated phospho-MAPKs in
LV protein extracts from 2-month-old WT and PKCy
 /  mice. The representative
experiment is shown. Relative fold inductions are shown, as determined by
densitometric analyses of western blots from three independentexperiments (n¼9
per genotype), using a-tubulin expression for normalization (**Po0.001 versus
WT). (D) RT-PCR analysis of the expression of ANF (atrium natriuretic factor),
a-SKA (a-skeletal actin), a-CAA (a-cardiac actin), b-MyHC (b-myosin heavy chain)
in 2-month-old WT and PKCy
 /  LVs. GAPDH expression was used to normalize
the reaction
PKCh and cardiomyocytes survival
R Paoletti et al
6
Cell Death and Diseaseundergo stress response, as shown by the progressive
increase in cell size, as well as by the upregulation of the
expression of fetal genes, such as ANF, a-SKA and b-myosin.
Indeed, the return to a pattern of fetal metabolism is
considered a common feature of a hemodynamically or
metabolically stressed heart.
26
Taken together, these data suggest that ablation of PKCy
resultsincardiomyocyteloss,which,inturn,promotescardiac
remodeling, ﬁbrosis and ventricular dilation; this indicates that
PKCy is required for cardiomyocyte survival, as it has
previously been shown for other cell types.
11,12 Indeed,
whereas no alterations were observed in prosurvival (ERKs)
Figure 5 PKCy ablation sensitizes CMCs to stress-induced cell death. (A) Immunoﬂuorescence analysis of serum-starved WT (a–b) and PKCy
 /  CMCs (c–d), either
treated (b and d) or not treated (a and c) with PE for 48h, using a-MyHC (green) and a-ANF (red) antibodies (arrows show perinuclear ANF protein expression). (B) (a) Area
determination in cultured WT and PKCy
 /  CMCs, either treated with or without PE for 48h. CMC area was measured in MF20
þve cells using the Scion Image Program
(n¼1000 cells per each condition; *Po0.01, **Po0.001, ***Po0.0001); (b) western blot analysis of WT and PKCy
 /  CMCs, treated with or without PE for 30min., as
indicated The blot was incubated with the a-Akt or the a-phospho-Akt antibodies. The level of activation was determined by densitometric analysis, as the phospho/total Akt
ratio (*Po0.01). Tubulin level of expression was used to ensure equal loading; (c) western blot analysis of WT and PKCy
 /  CMCs, treated with or without PE for 48h, as
indicated.Theblotwasincubatedwiththea-ANF,a-MyHCora-cardiactroponinI(cd-TnI)antibodies.Thelevelofexpression,determinedbydensitometricanalysis,with1.00
givenasthebasallevelofexpressioninWTCMCs,isalsoshown.***Po0.0001versusuntreatedWT;11Po0.001and1Po0.01versusuntreatedPKCy
 / .(C)Trypanblue
incorporation in WT and PKCy
 /  CMCs, treated with or without PE in for 48h. Parallel cultures were treated with 50mM Leu for 30min before being exposedto PE for 48h,
as indicated. Trypan blue-positive cells were counted (20 microscopic ﬁelds per each condition, from three independent experiments) and expressed as a percentage of the
total number of cells; **Po0.001 and ***Po0.0001). (D) TUNEL analysis in cultured WT and PKCy
 /  CMCs, treated with or without PE for 48h, as indicated. TUNEL-
positive nuclei were counted (20 microscopic ﬁelds per each condition, from three independent experiments) and expressed as the percentage of the total number of nuclei
(*Po0.01).(E)WesternblotanalysisofWTandPKCy
 / CMCs,treatedwithorwithoutPEfor4h,asindicated.Theblotwasincubatedwiththea-caspase-9antibody(upper
panel), or with the a-caspase-8 antibody (lower panel). Apoptosis-induced Jurkat cell lysate was used as the positive control (Cþ)
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Cell Death and Diseaseactivities, an increase in proapoptotic (p38 and JNK) activities
was observed in LVs lacking PKCy. Interestingly, PKCe and
PKCd are known to activate MAP kinase signaling pathways
in cardiomyocytes,
27 and the diastolic dysfunction and
interstitial ﬁbrosis observed in PKCe
 /  mice after pressure
overload, are associated with a decrease in ERK and an
increase in p38 and JNK phosphorylations, as the latter is
probably dependent on PKCd upregulation.
25 As no alteration
in PKCe or PKCd expression was observed PKCy
 /  hearts,
the results obtained in our study suggest that PKCy activity is
required to maintain the correct balance between MAPK
pathways and, consequently, to ensure physiological cell
survival. Several mouse models now show that cardiomyo-
cyte death itself may directly cause dilated cardiomyopathy.
28
Although no supporting data are available yet, it is possible
that PKCy activity is required on one hand to counterbalance
the PKCd-dependent activation of p38 and JNK, whereas, on
the other hand, to support the survival of PKCe-induced
proliferating cardiomyocytes. Intriguingly, the phenotype
observed in PKCe
 /  mice after pressure overload, wherein
PKCd is upregulated, presents many similarities to those
observed in basal condition when PKCy is ablated.
25
In keeping with in vivo observations, cultured CMCs lacking
PKCy acquire a hypertrophic-like phenotype, as shown by
both morphologicaland molecularanalyses;infact,increased
accumulation of both ANF and MyHC is evident in PKCy
 / 
CMCs, although Akt expression and phosphorylation are
not affected, suggesting that the phenotype observed is Akt
independent. Surprisingly, the lack of PKCy prevents phar-
macologically induced hypertrophy; rather, cell size de-
creases, and the expression of ANF and MyHC, and Akt
activation is prevented. Indeed, PKCy
 /  CMCs are more
susceptible to cell death than WT CMCs, both at basal
condition and after pharmacological or environmental stress-
induced stimuli. The fact that the death of PKCy
 /  CMCs can
beprevented bytreatmentwith leupeptin,a protease inhibitor,
shows that the observed cell death can be attributed to
protease activities. It is noteworthy that leupeptin preferen-
tially inhibits calpain activity, thereby highlighting a possible
role of this class of proteases in the cell death observed in our
study. Indeed, reduced expression of the regulatory myoﬁ-
brillar protein cd-TnI was observed in PKCy
 / . Troponins are
susceptible to proteolytic degradation by intracellular pro-
teases, such as calpain-I, caspases and matrix metallopro-
teinase-2, which occur in reversibly or irreversibly damaged
cardiomyocytes.
29,30 As a consequence, degradation pro-
ducts of troponins are detected in the serum of patients with
acute myocardial infarction, and it is considered as a reliable
clinical cardiovascular biomarker.
31 Accordingly, TUNEL
analysis shows that the observed cardiomyocyte death is
mainly due to apoptosis, and, in particular, activation of the
intrinsic cell death pathway, as caspase-9, but not caspase-8,
cleavage was observed in PKCy
 /  CMCs, and was further
increased after PE exposure. The involvement of PKCy in this
pathway is supported by a number of observations in T cells
wherein it is well documented that PKCy promotes cell
survival by both inhibiting the proapoptotic factor Bad and
activating the antiapoptotic factor BclxL.
11,12
Further experiments are warranted to more accurately
deﬁne the molecular mechanisms underlying the observed
phenotypeand therelativecontributionofthePKCy-regulated
signaling pathways. PKCy, as a member of the nPKCs
subfamily, is known to mediate the nuclear export of class II
HDACs,probably byregulating PKCm/PKD activity.
15,19 Class
II HDACs act as negative regulators of pathological cardiac
remodeling through their association with the myocyte
enhancer factor-2 transcription factor and other prohyper-
trophic transcriptional regulators.
32 However, recent data,
based on a PKD1 conditional knock out, suggest that PKD1 is
required to actually transduce stress stimuli involved in
pathological cardiac remodeling in vivo.
33 As PKD1 is a
commonsubstrateforallmembersofthenovelclassofPKCs,
it isconceivable thatPKCy may also have a speciﬁcrole in the
regulation of heart maintenance, besides exerting its activity
on PKD functions.
In conclusion, the results reported in this paper show that
PKCy ensures cardiac muscle homeostasis, at least in part,
by preventing cardiomyocyte cell death in response to work
demand and neuro-hormonal signals, to which heart cells are
continuously exposed. This study advances the understand-
ing of cellular mechanisms responsible for preservation of
myocardial integrity, and the observation that PKCy can be
considered a key protein for cardiac structure and function
under physiological conditions, may thus be instrumental for
future development of therapeutic strategies for the treatment
of pathological cardiac remodeling and heart failure, using
select PKCy isoform modulators.
Materials and Methods
Animals. PKCy
 /  mice (C57BL/6J background strain) were kindly provided by
Littmann and colleagues.
34 For in vivo studies, 2-month-old male mice were used
throughout the experiments, unless otherwise speciﬁed. The animals were housed
in the Histology Department accredited animal facility. All the procedures were
approved by the Italian Ministry for Health and conducted according to the US
National Institutes of Health guidelines.
Antibodies. The following primary antibodies were used: the antimyosin heavy-
chainMF20,
35theanti-ANF(Bachem,Bubendorf,Switzerland);theanti-caveolin-3,the
anti-PKC-a,- d,- e,- Z,- y and the anti-phospho
Thr538 PKCy (BD Bioscience, Franklin
Lake, NJ, USA); the anti-Akt, the anti-phosphoAkt, the anti-phosphoGSK3b and the
anti phospho-p38 (Cell Signalling Inc., Danvers, MA, USA); the anti-caspase-9 (Assay
Designs,AnnArbor,MI,USA);theanti-caspase-8(SantaCruzBiotec,SantaCruz,CA,
USA); the anti-a-tubulin (Sigma-Aldrich, St. Louis, MO, USA).
Transthoracic echocardiography. Echocardiographic analysis was
performed using a high-resolution echocardiograph (VeVo 770, Visualsonics, Toronto,
ON, Canada) equipped with a 33MHz transducer. End-diastolic and end-systolic
intraventricular septum (IVSTd, IVSTs), posterior wall thickness (PWTd, PWTs) and LV
internal diameters (LVEDD, LVESD) were measured. Percentage fractional shortening
(%FS) and relative ejection fraction (EF) were calculated using standard formulas:
%FS ¼½ ð LVEDD   LVESDÞ=LVEDD  100
EF ¼½ ð LVEnd   diastolicvolume   LVEnd   systolicvolumeÞ=
LV End   diastolicvolume  100
LV hemodynamics. Mice were anesthetized with an intraperitoneal injection
of ketamine/xylazine (80/10mg/kg body weight), and inotropic and lusitropic
functions were evaluated by measuring intraventricular volume and pressure using
amicromanometercatheter(Millar1.4F,SPR671,MillarInstruments,Houston,TX,
USA) positioned in the LV through right common carotid artery cannulation.
36 An
estimate of systolic and diastolic LV performance was yielded by a series of
pressure–volume loops of consecutive cardiac cycles.
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Cell Death and DiseaseThoracic aortic constriction. Thoracic Aortic Constriction (TAC) was
imposed between the truncus anonymous and the left carotid artery using a
7-0 nylon suture ligature, as described previously.
36 A separate group of mice
underwent the same surgical procedures, but without aortic stenosis (sham
operated). Fifteen minutes after TAC, simultaneous left and right carotid pressures
were measured under anesthesia, to assess the degree of pressure load.
Immediately after, the hearts were removed, the chambers dissected, weighed and
processed for protein extraction.
Cellcultures. Neonatalmouseventricularmyocytes(CMCs)wereisolatedfrom
the LVs of 1–3-day-old mice. In brief, cells were extracted by multiple rounds of
15min at 371C in ADS buffer (116mM NaCl, 5.4mM KCl, 18mM HEPES, 0.9mM
Na2HPO4, 5.5mM glucose, 0.4mM MgSO4, pH 7.35) containing Collagenase Type
2 (108Units/ml, Worthington, Lakewood, NJ, USA) and Pancreatin (0.9mg/ml,
Sigma-Aldrich.Thecellswerethensuspendedina4:1ratioofDulbecco’smodiﬁed
Eagle’s medium and M-199 culture medium, supplemented with 10% horse serum,
5% fetalcalf serum,2mMglutamine(all fromGibcoInvitrogen,Carlsbad,CA,USA)
and 1% AraC (Sigma-Aldrich). A 90-min preplating step was performed. The ﬁnal
cellsuspensionwasplatedoncollagen-coateddishesina371C,5% CO2incubator.
After 24h, the medium was replaced with serum-free medium and cells were
culturedfor24hbeforebeingexposedtotreatmentfortheadditionalperiodsoftime
indicated. CFs were enriched with the preplating, and cultured on uncoated culture
dishes in a 371C, 5% CO2 incubator.
Histological and immunoﬂuorescence analyses. For histological
analyses, heart cryosections were ﬁxed in 4% paraformaldehyde (Sigma-Aldrich)
andstainedwithhematoxylin/eosinorGomori’strichrome(bothfromSigma-Aldrich)
solutions. Fibrotic areas were measured using the Image J software (NIH,
Bethesda, MD, USA). For immunoﬂuorescence analysis, cryosections were ﬁxed in
4% paraformaldehyde, as described above, whereas cultured cells were ﬁxed in
ethanol/acetone (1:1 ratio) at  201C for 20min, and processed as described
previously.
35 Samples were examined under a Zeiss Axioskop 2 Plus ﬂuorescence
microscope (Zeiss, Gottingen, Germany), as mentioned above. The mean CMC
CSA in the heart tissue, as well as the mean cell area in cultured CMCs, were
measuredusingtheScionImage4.0.3.2software(NIH,Bethesda,MD,USA).CMC
number in the heart tissue was determined by counting caveolin-3 and myosin
þve
cells per microscopic ﬁeld.
Preparation of protein extracts and western blot analysis. For the
total protein extract preparation, tissue samples or cell pellets were homogenized in
RIPAbuffer(10mMTrispH7.5,150mMNaCl,1%NP-40,0.5%NaDesoxycholate,
0.1%SDS,10%glycerol,0.2mMEDTA,200mg/mlleupeptine,10mg/mlaprotinine,
1mM PMSF, 10mM Na Fluorure, 1mM Na Orthovanadate). For the preparation of
subcellular protein fractions, LVs were homogenized in homogenization buffer
(20mM Tris pH 7.5, 2mM EGTA, 2mM EDTA, 250mM sucrose, 5mM DTT, 1mM
PMSF, 200mg/ml Leupeptin, 10mg/ml aprotinin) and incubated 30min on ice.
Samples were then spun at 100000 g for 30min at 41C. The supernatant was
saved as cytosolic fraction, whereas the remaining pellet was suspended in
homogenization buffer containing 0.1% Triton X-100, and incubated for 30min on
ice. At the end, the samples were spun at 100000 g for 30min at 41C, and the
remaining supernatant was saved as the particulate fraction. An equal amount of
each sample was loaded onto 10% SDS-polyacrylamide gels and transferred to a
nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). The
membranes were then incubated with the appropriate primary antibodies.
Alkaline phosphatase-conjugated goat anti-mouse IgG (Roche Applied Science,
Indianapolis, IN, USA) or alkaline phosphatase-conjugated goat anti-rabbit IgG
(Zymed Laboratories, San Francisco, CA, USA) were used as secondary
antibodies, and immunoreactive bands were detected with the CDP-STAR
solution (Roche Applied Science), according to the manufacturer’s instructions.
Densitometric analysis was performed using the Aida 2.1 Image software (Raytest,
Straubenhardt, Germany); a-tubulin optic density was used for normalization.
RNA preparation and RT-PCR analysis. Total RNA from cultured cells
was isolated using the High Pure RNA Isolation Kit (Roche Applied Science),
whereas total RNA from LVs was isolated using TRIZOL Reagent (Invitrogen),
according to the manufacturers’ instructions. cDNA was synthesized using the
Superscript III system (Invitrogen), and PCR ampliﬁed using Taq Polymerase
(Takara Bio Inc., Shiga, Japan). The sequences of primers used for PCR were as
follows: a-MyHC, forward ACCGTCTGGACGAGGCAGAGCAGA, reverse CGTC
GTGCATCTTCTTGGCACCAA (annealing temperature 621C, expected band
420bp); b-MyHC, forward CAGCACCGTCTGGACGAGGCAGAG, reverse
ATTCAGGCCCTTGGCACCAATGTC (annealing temperature 621C, expected
band 420bp); ANF, forward CAGAGTGGGCAGAGACAGCA, reverse TTGCTTTT
CAAGAGGGCAGATCTAT (annealing temperature 651C, expected band 389bp);
a-cardiac actin, forward TGTTACGTCGCCTTGGATTTTGA, reverse AAGAGAG
AGACATCTCAGAAGC (annealing temperature 651C, expected band 494bp);
a-skeletal actin, forward TATTCCTTCGTGACCACAGCTGAACGT, reverse CGC
GAACGCAGTCGCGGGTGCGC (annealing temperature 651C, expected band
560bp); aSMA, forward TCAGGGAGTAATGGTTGGAATG, reverse TCGGCAG
TAGTCACGAAGGAA (annealing temperature 581C, expected band 495bp);
COL1a1, forward GGGCGAGTGCTGTGCTTTCTG, reverse CCTCGGTGTCCC
TTCATTCCA (annealing temperature 581C, expected band 537bp); COL3a1,
forward AGCCACCTTGGTCAGTCCTA, reverse TTCCTCCCACTCCAGACTTG
(annealing temperature 551C, expected band 403bp); TGFb1, forward CAAGGA
GACGGAATACAGGGCT, reverse CGCACACAGCAGTTCTTCTCTGT (annealing
temperature 551C, expected band 260bp); PCNA, forward TCCTTGGTACA
GCTTACT, reverse TGCTAAGGTGTCTGCATT (annealing temperature 521C,
expected band 165bp); Cyclin D1, forward GTGCCATCCATGCGGAA, reverse
GGATGGTCTGCTTGTTCTCA (annealing temperature 521C, expected band
362bp); GAPDH, forward ATGTTCCAGTATGACTCCACTCACG, reverse GAGTT
GCTGTTGAAGTCGCAGGAGACAA (annealing temperature 631C, expected band
734bp). The same reaction proﬁle was used for all the primer sets: an initial
denaturation at 951C for 5min, followed by 30 cycles of 951C for 1min; primer-
speciﬁc annealing temperature for 1min; 721C for 2min; ﬁnally, 7min at 721C.
Ampliﬁcation of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
housekeeping transcript was used for normalization. PCR products were
separated on 1% agarose gel in a TAE buffer containing ethidium bromide, and
digitized images were obtained using a CCD camera Detection System (Diana II,
Raytest, Straubenhardt, Germany).
BrdU assay. Two-month-old mice were intraperitoneally injected with BrdU
(25mg/kg, Roche Applied Science). Mice were killed after 24h, and 7mm
cryosections were prepared from the hearts. Cultured cells were incubated with
BrdU labeling medium (BrdU Labeling and Detection kit I, Roche Applied Science)
for 1h and then ﬁxed. BrdU incorporation was detected according to the
manufacturer’sinstructions,andanalyzedunderan epiﬂuorescence ZeissAxioskop
2 Plus microscope, equipped with a CCD camera.
Cell death assays. Cell viability was determined on ﬁxed cells stained with
0.08% trypan blue dye; nuclei were counterstained with Hoechst 33342 (Sigma-
Aldrich). Cell apoptosis was determined by TUNEL reaction (Roche Applied
Science). At the times indicated, cells were ﬁxed and incubated for 1h at 371C with
the TUNEL mixture. Positive nuclei were detected under an epiﬂuorescence Zeiss
Axioskop 2 Plus microscope, as described above.
Statistical analysis. All data are expressed as mean±S.E.M. Statistical
hypotheses were tested by Student’s t-test or one-way ANOVA, followed by Bonferroni’s
post hoc test, as appropriate. A Po0.01 was considered statistically signiﬁcant.
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